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Organopalladium compound 7b targets mitochondrial
thiols and induces caspase-dependent apoptosis in
human myeloid leukemia cells
VWR Moraes1, ACF Caires2,w, EJ Paredes-Gamero3 and T Rodrigues*,1
The advances in the treatment of chronic myeloid leukemia (CML) during the last years were also accompanied by the
development of evading strategies by tumor cells, resulting in chemotherapy resistance in some patients. Patented
organopalladium compounds derived from the reaction of N,N-dimethyl-1-phenethylamine (dmpa) with [1,2-ethanebis(diphe-
nylphosphine)] (dppe) exhibited a potent antitumor activity in vivo and in vitro in melanoma cells. We showed here that the
cyclopalladated derivative [Pd2(R(þ ))C
2, N-dmpa)2(l-dppe)Cl2], named compound 7b, was highly effective to promote cell death
in the K562 human leukemia cells and its mechanisms of action were investigated. It was shown that compound 7b was able to
promote exclusively apoptotic cell death in K562 cells associated to cytochrome c release and caspase 3 activation.
This cytotoxic effect was not observed in normal peripheral mononuclear blood cells. The compound 7b-induced intrinsic
apoptotic pathway was triggered by the protein thiol oxidation that resulted in the dissipation of the mitochondrial
transmembrane potential. The preventive effect of the dithiothreitol on the compound 7b-induced cell death and all downstream
events associated to apoptosis confirmed that death signal was elicited by the thiol oxidation. These findings contribute to
the elucidation of the palladacycle 7b-induced cell death mechanism and present this compound as a promising drug in the CML
antitumor chemotherapy.
Cell Death and Disease (2013) 4, e658; doi:10.1038/cddis.2013.190; published online 6 June 2013
Subject Category: Cancer
Chronic myeloid leukemia (CML) is a clonal myeloproliferative
disorder of the hematopoietic system. Its incidence is estimated in
5000 new cases per year in the United States.1 This type of
malignancy is characterized by a genetic abnormality, which is
found in up to 95% of patients and considered the hallmark of this
disease. In healthy individuals, the ABL gene is located on
chromosome 9, whereas the BCR gene is located on chromo-
some 22. In the CML chromosome 9 and 22 exchange part of
their DNA (translocation), and BCR and ABL join together,
resulting in the abnormal gene BCR-ABL. This new mixed
chromosome containingBCR-ABL is calledPhiladelphia chromo-
some.2 It is noteworthy that the consequence of this translocation
is the fusion gene BCR-ABL, which has an enhanced tyrosine
kinase activity and is responsible for themalignance of this type of
cancer, as BCR-ABL alters the cell cycle.3
The treatment of CML has improved considerably in the last
years. Advances in the field of drug development and
the comprehension of the role of BCR-ABL tyrosine kinase
activity in this cancer allowed the development of tyrosine
kinase inhibitors (TKI). The first TKI approved for the treatment
of CMLwasmesylate imatinib, a selective and potent inhibitor of
BCR-ABL.4 Despite the successful results achieved with this
drug, resistance is still a recurrent issue encountered in the
treatment of this cancer in some patients. The mechanisms of
imatinib resistance are classified according to its dependence
on BCR-ABL. Drug resistance related to BCR-ABL are themost
common and it is found in themajority of patients. It involves the
amplification or overexpression of BCR-ABL and point muta-
tions in the ABL kinase domain. Other mechanisms indepen-
dent of BCR-ABL include multidrug-resistance expression and
activation of downstream signaling molecules, such as Src
kinases.5–7 Multiple strategies have been developed to over-
come imatinib resistance, which includes the use of a second
generation TKI-like dasatinib and nilotinib, other novel agents
still in clinical trial, non-TKI-based therapy, dose escalation of
imatinib and allogeneic stem cell transplant.8,9 This highlights
the need for the development of new agents in the treatment of
CMLable to selectively kill tumor cells and be an effective option
in the treatment of this cancer.
Recently, the importance of the organopalladium chemistry
was recognized with the Nobel Prize in Chemistry to the
‘Suzuki coupling’, a palladium-catalyzed cross coupling
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reaction by Professor Richard F. Heck of the University of
Delaware in Newark, Delaware, USA; Professor Ei-ichi
Negishi of Purdue University in West Lafayette, Indiana,
USA and Professor Akira Suzuki of Hokkaido University in
Sapporo, Japan.10 In fact, the versatility of such class of
compounds has allowed its application in several fields,
including Medicine. The synthesis of palladium compounds
began in 1980 due to its similarity in structure to cisplatin.
However, the first synthesized compounds exhibited little
stability in biological systems, which was later solved by the
use of ligands.11,12
Cyclopalladated complexes derived from the reaction of
N,N-dimethyl-1-phenethylamine (dmpa) with [1,2-ethanebis
(diphenylphosphine)] (dppe) more stable and less toxic were
synthesized and patented worldwide. Currently such com-
pounds are under preclinical phase evaluation and they have
exhibited a potent antitumor activity in vivo and in vitro at
relatively low concentrations.13 It was demonstrated that this
compound was able to induce mitochondrial permeabilization
due to the oxidation of protein thiol groups in isolated rat liver
mitochondria related to its cytotoxicity.14 Analog compounds
with the coordinating ligand ferrocene have also exhibited its
effects on lysosomes, resulting in lysosomal membrane
permeabilization and cathepsin B release.15,16
In this work, we investigated the induction of cell death by
the palladacycle [Pd2(R(þ )C2, N-dmpa)2(m-dppe)Cl2],
named compound 7b, in a well-known resistant leukemia cell
line. Our results showed that the compound 7b induced a
caspase-dependent apoptosis in K562 leukemia cells,
with involvement of the intrinsic pathway triggered by
mitochondrial thiol oxidation.
Results
Screening of the cytotoxicity of the palladacycle 7b in
K562 cells. Cell viability was determined in order to screen
the cytotoxic potencial of the organopalladated compound
7b against K562 leukemia cells. By using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) reduction test, it was shown that increasing concen-
trations of compound 7b decreased the cell viability in a
concentration-dependent manner (Figure 1, closed circles).
To avoid misinterpretation, cell viability was also measured
by the trypan blue exclusion test and similar results were
obtained (closed triangles). Both methods exhibited similar
results excluding a possible redox interference of compound
7b with the MTT assay. The EC50 values obtained were
about 1.2 mM for both methods, demonstrating the high
cytotoxicity of the drug in this myeloid leukemia model. As
our group had previously observed (Santana et al.14) that this
compound was able to promote mitochondrial dysfunction
due to the oxidation of protein thiol groups in isolated
rat liver mitochondria, K562 cells were pre-incubated with
dithiothreitol (DTT). As observed in Figure 1a, DTT was able
Figure 1 Viability of K562 and peripheral mononuclear blood cells after treatment with compound 7b for 24 h. (a) K562 cell viability was evaluated by the MTT reduction
endpoint test (closed circles) and trypan blue exclusion assay (triangles). Cells (1 105/ml) were incubated with different concentrations of the drug. The effect of the cells-
pre-incubation with 1 mM DTT was also assessed by MTT (open circles). The percentage of viable cells was calculated in relation to control (untreated), considered as 100%.
(b) The effect of the thiol antioxidants 1 mM NAC and 1 mM GSH on K562 cells viability was assessed by MTT reduction assay. Cells (1 105/ml) were pre-incubated with
NAC (white bars) or GSH (gray bars) for 30 min and then incubated with 0.5, 1 and 1.5mM compound 7b for 24 h. The percentage of viable cells was calculated in relation to
control (untreated), considered as 100%. The data are presented as mean±S.E.M. of three independent experiments. *Statistically different from control (Po0.05).
(c) Mononuclear blood cells (1 105/ml) were stimulated with 5mg/ml phytohemagglutinin and incubated with different concentrations of the drug (open circles) in comparison
with K562 cells (closed circles)
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to prevent compound 7b-induced cell death completely
(open circles), indicating the involvement of thiol oxidation
in the cytotoxicity of compound 7b. Also, the pre-incubation
with N-acetylcysteine (NAC) and reduced glutathione (GSH)
resulted in the inhibition of palladacycle-induced cell death
(Figure 1b). Surprisingly, as observed in the Figure 1c,
peripheral mononuclear blood cells were not affected by
compound 7b (open circles) at the same concentration range
in relation to K562 tumor cells (closed circles).
Compound 7b induces DTT-sensitive apoptosis in
K562 cells. K562 cells were doubled stained with annexin
V-fluorescein isothiocyanate (FITC)/propidium iodide
(PI) and analyzed by flow cytometry to investigate the type
of cell death induced by compound 7b. As observed in
Figure 2a, the cells incubated with compound 7b exhibited
predominantly positive labeling for annexin V (black bars)
and also annexin V-FITC/PI double staining (white bars),
indicating the phophatidylserine externalization that occurs
during apoptotic process. Quantification of the cytometry
data of replicates revealed an expected concentration-
dependent behavior and the decrease in the number of
viable cells (An /PI ) matched with MTT and Trypan blue
results (Figure 2b). Compound 7b-induced apoptosis was
completely prevented by DTT (Figures 2a and b). In addition,
to confirm the occurrence of apoptotic cell death induced by
compound 7b in these leukemia cells, the morphological
nuclear alterations were observed in 4´,6-diamidino-2-pheny-
lindole (DAPI)-stained K562 cells. Compound 7b induced
nuclear fragmentation with chromatin condensation and
apoptotic body formation, evidenced by the representative
image obtained by confocal fluorescence microscopy
(Figure 2c). Figure 2d shows the percentage of apoptotic
nuclei in compound 7b-treated cells versus 7b non-treated
cells by counting a hundred cells in widefield fluorescence
microscopy. Compound 7b-treated cells exhibited more
than 60% of apoptotic nuclei and the pre-incubation with
DTT decreased this number below 10%.
Compound 7b promotes protein thiol oxidation
associated to mitochondrial depolarization in K562
cells.
In order to directly access the participation of the thiol redox
state in the compound 7b-induced cell death, the reduced
thiol groups of cellular proteins and the GSH were measured
after exposure to 1.5 and 3.0 mM compound 7b in the same
experimental conditions of cell viability assays. Compound
7b oxidized protein thiol residues that is responsive to the
concentration (Figure 3a) and, as expected, the pre-incuba-
tion with DTT prevented this effect. Thiol oxidation in
Ca2þ -loaded mitochondria is thought to trigger the opening
of the mitochondrial permeability transition pore with the
release of pro-apoptotic proteins.17,18 The mitochondrial
transmembrane potential (DC) was evaluated in order to
investigate the occurrence of mitochondrial permeabilization
related to apoptosis induced by the compound 7b. The
addition of compound 7b in digitonin-permeabilized K562
cells resulted in an immediate dissipation of the mitochon-
drial DC (Figure 3b) at the same concentration range that
induced cytotoxicity. Such dissipation was inhibited by DTT,
showing that it is preceeded by the thiol oxidation. Ca2þ
chelators EGTA or BAPTA-AM had no effect on compound
7b-induced DC dissipation (not shown). The same results
were found in intact cells loaded with JC-1 analyzed by
flow cytometry (Figure 3c). In this experiment, control cells
(absence of drug) emitted red fluorescence due to high DC.
However, compound 7b-treated cells showed progressive
loss of red J-aggregate fluorescence with the increase of
green fluorescence after 24 h incubation due to mitochondrial
transmembrane dissipation and DTT prevented it.
Compound 7b induced caspase-dependent apoptosis
throughout the mitochondrial intrinsic pathway. The
triggering of mitochondrial permeability transition may result
in apoptotic or necrotic cell death.19 The evidences pre-
sented here pointed to compound 7b-induced apoptosis. In
order to investigate whether thiol oxidation and mitochondrial
depolarization were involved in the cell death, it was
investigated the release of cytochrome c from mitochondrial
to cytosol in K562 cells incubated with compound 7b.
To estimate the cytochrome c release, we performed a
double-staining confocal fluorescence imaging using
MitoTracker red in combination with an anti-cytochrome
c antibody immunostaining. As expected, in the absence of
drug (control) cytochrome c (green) was co-localized with
MitoTracker red as evidenced by yellow/orange color,
indicating that this protein is confined in mitochondria
(Figure 4a). After a 12-h exposure to compound 7b,
cytochrome c was redistributed all over the cytosol and did
not co-localize with MitoTracker, indicating that cytochrome
c was no longer confined in mitochondria. Again, DTT
reversed this effect as shown by the co-localization of
cytochrome c with MitoTracker red. Cytochrome c is a mobile
electron transporter in the respiratory chain and also
participates in the apoptosis, triggering through the apopto-
some formation and caspase activation. Thus, we also
investigated the compound 7b-induced caspase 3 activation
by flow cytometry (Figure 4b). The dislocation of the
histogram to higher fluorescence values indicated caspase
activation (black solid line) and the pre-incubation with DTT
prevented it (dotted line), indicating that the oxidation of thiol
residues results in mitochondrial permeabilization with
release of pro-apoptotic proteins and caspase activation.
The quantification was presented in the Figure 4c.
Discussion
Cancer cells exhibit genetic and epigenetic mutations that
may result in resistance to cell death.20 Mutations in the
p53 tumor suppressor gene are relatively common in a
variety of tumors, including human myeloid leukemia, and
result in the absence of DNA damage protection, leading to
an extensive resistance to apoptosis.21,22 Another genetic
mutation responsible for the pathogenicity of CML is the
Philadelphia chromosome, originated by a translocation
between chromosomes 9 and 22. Such translocation
originates the BCR-ABL gene that has an enhanced tyrosine
kinase activity, leading to tumor progression and resistance
to cell death.23 Therefore, drug resistance is the major
challenge in cancer chemotherapy. It evidences the need for
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the development of new drugs or new targets to improve
efficiency and selectivity to kill cancer cells. K562 cells exhibit
both alterations mentioned above.
The application of organometallic compounds in the
antitumor chemotherapy began in 1964 with cisplatin. Since
then, several structural derivatives have been synthesized in
order to increase the efficacy and to overcome the toxicity/
side effects of the original drug.24,25 Because of the chemical
similarity between platinum and palladium, organopalladate
complexes started to stand out as a promising alternative to
cancer therapy due to their high potency and the reaching of
molecular targets. However, the first synthesized compounds
presented low stability in biological system that was solved
with the use of chelating ligands.12 The organometallic
palladacycle used in this study was synthesized and recently
patented worldwide. It has been shown that the compounds
derived from the reaction of dmpa with dppe exhibit a
potent antitumor activity in vivo and in vitro at relatively low
concentrations.13,16 Nevertheless, few advances have been
made concerning themolecular basis of the antitumor effect of
these compounds. In this work, we screened the cytotoxic
effects of the organopalladated compound 7b in a BCR/ABL-
positive K562 leukemia cell line and the molecular mechan-
isms that account for cell death were also investigated.
Figure 2 Compound 7b-induced apoptosis in K562 cells. (a) Representative flow cytometry density plots of the double label with annexin V-FITC and PI. K562 cells
(1 105/ml) were incubated for 24 h in the presence of different concentrations of the compound 7b. Cells were also pre-incubated with 1 mM DTT for 30 min. At least 10 000
cells were analyzed per sample and the figure is representative of three experiments made in triplicate. (b) The quantification was presented as mean±S.E.M.; An (Annexina
V-FITC) and PI. (c) Nuclear alterations were accessed by DAPI staining and a representative image was acquired in a confocal microscopy. Each sample was done in
duplicate and the number of apoptotic cells was expressed as a percentage of the total number of cells. White bars represent 5.0mM. (d) The quantification of the apoptotic
nuclei was performed by counting of 100 cells per field of view per sample in three different fields. * and # pairs are statistically different (Po0.05)
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Our results evidenced the in vitro cytotoxic activity of the
palladacycle 7b in CML K562 cells at relatively low concen-
trations (below 1.5mM). Cytotoxicity induced by the com-
pound 7b exhibited selectivity, as normal cells were not
affected at the same concentration. Such selectivity was also
observed from ferrocen-derived palladacycles.16 The cyto-
toxicity of compound 7b was first reported in a melanoma
model with apparent inhibition of the respiratory activity.13
It has been recently demonstrated that its enantiomer
compound 7a exhibited in vitro and in vivo trypanocidal effects
associated to the mitochondrion structure disruption and also
cytotoxicity against B16F10-Nex melanoma cells.26,27
Besides the role of mitochondria in energy production,
theses organelles concentrate lethal weapons to orchestrate
cell death, and such feature makes them a strategic target
in the antitumor chemotherapy.28 Recently, we demons-
trated the induction of mitochondrial permeabilization in
isolated rat liver mitochondria by the compound 7b. Such
permeabilization was promoted by the oxidation of protein
thiol residues.14 The oxidation of protein thiol groups in
mitochondrial membranes promoted by free radicals or thiol
oxidizing agents results in the opening of the mitochondrial
permeability transition pore.17,29 The opening of this large
conductance channel causes the dissipation of the mitochon-
drial DC, loss of the matrix components, increased reactive
oxygen species production, swelling and outer membrane
rupture.30 All these morphological and functional mitochon-
drial alterations may be accompanied by the release of
apoptogenic factors to cytosol, including cytochrome c, that
activate intermediate and effector caspases, resulting in the
execution of cell death.31
The organopalladated compound 7b was able to trigger
exclusively a caspase-dependent apoptotic cell death pro-
gram in K562 leukemia cells through the intrinsic
pathway, characterized by mitochondrial permeabilization,
cytochrome c release and caspase 3 activation. This is a
Figure 3 Oxidation of the protein thiol groups and dissipation of the mitochondrial DC by compound 7b in K562 cells. (a) Cells (5 105/ml) were incubated for 24 h in the
presence of the compound 7b. Reduced thiol groups were measured spectrophotometrically at 412 nm by using DTNB. Absorbance values were converted in percentage in
relation to control and presented as mean±S.E.M. Numbers are drug concentrations in mM. *Statistically different from control (Po0.05) and #statistically different from
compound 7b (Po0.05). The amount of protein thiol groups in control was 2.33mM. (b) Cells (5 105/ml) were incubated in a buffer containing 250 mM sucrose, 10 mM
HEPES, 2 mM KH2PO4, 0.5 mM EGTA, 0.5% (w/v) BSA, 5 mM MgCl2 (pH 7.2) plus 5 mM succinate and 1.0mM rhodamine 123, in the presence of the compound 7b. Traces
are representative of three independent experiments and the numbers are concentrations inmM. DC was generated by uptake of succinate by cells after selective
permeabilization with 0.004% (w/v) digitonin. Fluorescence arbitrary units (a.u.). (c) Cells (1 105/ml) were incubated with compound 7b (1.25 and 1.5mM) for 24 h. Later,
JC-1 was added and the samples were analyzed by flow cytometry. The uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone (10 mM) was used as positive control.
Figure is representative of three experiments made in triplicate. DTT (1.0 mM) was pre-incubated with cells for 30 min
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noteworthy feature as it was shown that leukemia cells
were insensitive to cell death induction via the extrinsic
pathway due to the downregulation of CD95 expression.32
Despite the potency and specificity of compound 7b to
induce apoptosis in K562 leukemia cells, our results also
elucidated the molecular mechanisms involved in the cell
death pathway and the proposed sequence of events elicited
by compound 7b that culminated in cell death is presented in
the Scheme I.
The reactivity of compound 7b with protein thiol groups,
including those located in mitochondrial membranes, was
responsible for triggering cell death in this leukemia model.
The cell death induced by compound 7b in K562 cells
was completely inhibited by the thiol reducing agent DTT.
Interestingly, DTT also inhibited the mitochondrial permeabi-
lization (evaluated indirectly by the dissipation of the DC) and
all downstream events, suggesting that mitochondria are the
main target of the palladacycle. The specificity of this
oxidation was proposed, as GSH was not oxidized by the
compound 7b and probably was promoted by the partition of
the drug between the hydrophilic compartments and mem-
branes. Other thiol reactants GSH and NAC, but not the
antioxidant butylhydroxytoluene, were able to inhibit the cell
death promoted by compound 7b. Furthermore, after 24 h of
incubation compound 7b did not promote the increase in the
2´,7´-dichlorofluorescein fluorescence (not shown), indicating
that the thiol oxidation was not mediated by free radicals.
In summary, our results suggest that compound 7b
is a potent and specific apoptosis inducer in K562 cells.
Considering that apoptotic cell death is an important
regulatory program to prevent cancer development and that
leukemia cells have been able to escape from extrinsic
apoptotic pathways, resulting in chemotherapy resistance,
our study contributes to the preclinical screening of the
cytotoxicity of the palladacycle 7b in a resistant CML model
and provides a better comprehension of themolecular basis of
cell death induced by this drug.
Materials and Methods
Cell culture. K562 cells, a CML cell line that expresses the BCR-ABL gene,
were grown in suspensions in RPMI-1640 medium, pH 7.2, supplemented with
10% fetal bovine serum (Gibco SBF, Invitrogen, Grand Island, NY, USA), 100 U/ml
penicillin and 100mg/ml streptomycin. Cells were maintained in culture flasks at
37 1C in 5% CO2 atmosphere (Sanyo MCO-20AIC, Osaka, Japan).
Biphosphinic palladacycle complex [Pd2(R(þ )C2, N-dmpa)2
(l-dppe)Cl2]. The cyclopalladated complex 7b used in this study was derived
from dmpa complexed to dppe and synthesized as described in Rodrigues et al.13
Its chemical structure is shown in Chart 1. The compound was diluted to 10 mM in
DMSO (stock solution), and for in vitro assays it was diluted to the final
concentration in water.
Cytotoxicity assays. K562 cells or peripheral mononuclear blood cells
(1 105/ml) were incubated for 24 h in 96-well microplates in the presence of
different concentrations of compound 7b. The cytotoxicity was accessed by MTT
reduction test and by trypan blue dye exclusion assay.33 The peripheral
mononuclear blood cells was pre-incubated for 4 h with 5mg/ml phytohemagglu-
tinin before the addition of the drug. For the MTT reduction test, at the end of the
incubation period, 0.25 mg/ml MTT was added followed by 4 h incubation. Then
100ml of 10% SDS prepared in 0.01 M HCl was added and mixed thoroughly to
dissolve the formazan crystals at 37 1C. Plates were read at 630 nm (Microplate
Reader Biotek ELX 800, BioTek Instruments, Inc., Winooski, VT, USA) and the cell
viability was determined in relation to control performed in the absence of
Figure 4 Cytochrome c release and caspase 3 activation promoted by compound 7b. (a) Confocal laser scanning microscope images showing MitoTracker red
fluorescence (red), cytochrome c (green), DAPI staining (blue) in merged images (yellow indicates pixels of co-localization) in K562 cells. The cells were either untreated
(control) or exposed to 1.25mM compound 7b with or without DTT (1 mM) for 12 h. White scale bars represent 5.0mM. (b) Cells (1 105/ml) were incubated for 24 h in the
presence of 1.25mM compound 7b. Cells were also pre-incubated with 1 mM DTT for 30 min. Caspase 3 activation was accessed by flow cytometry using an anti-active
caspase 3 antibody conjugated with FITC and the data quantification was made by using geometrical mean of three independent experiments (c). * and # pairs are statistically
different (Po0.05)
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compound 7b, and considered as 100%. For the Trypan blue exclusion assay,
after the addition of 0.016% trypan blue in the cell suspension, the cells were
counted using a hemacytometer under optical microscopy. Each compound 7b
concentration was tested in three different experiments, ran in triplicate. It was also
been evaluated that the effect of some modulators in compound 7b induced cell
death: 1 mM DTT, 1 mM NAC, 1 mM GSH, 10 mM BAPTA-AM and 1 mM EGTA,
by pre-incubation of K562 cells with these compounds for 30 min.
Annexin V-FITC/PI double-staining and flow cytometry analysis.
After treatment with different concentrations of compound 7b for 24 h, K562 cells
were centrifuged and resuspended in binding buffer (0.01 M HEPES (pH 7.4)
0.14 M NaCl and 2.5 mM CaCl2) at a ratio of 1 105 cells/ml. The suspensions
were transferred to 5 ml tubes and 5 ml Annexin V-FITC (BD Biosciences, San
Jose, CA, USA) plus 5mg/ml PI (BD Biosciences) were added. The cells were
incubated at room temperature for 20 min and after the addition of 0.3 ml of
binding buffer, the analysis was performed in a FACSCalibur flow cytometer using
the CellQuest software (BD Biosciences) (10 000 events were collected per
sample). Experimental controls were performed with cells treated only with the
medium. Data were presented as media±S.E.M. of the triplicates.
Measurement of active caspase 3. Caspase 3 activity was measured by
flow cytometry. K562 cells (1 105 cells/ml) were treated with 1.25 mM compound
7b for 24 h. Then cells were fixed with 2% paraformaldehyde in PBS for 30 min
and permeabilized with 0.01% saponin in PBS for 15 min at room temperature.
Cells were then collected and incubated with Anti-Active-Caspase-3 monoclonal
antibody conjugated with FITC (BD-Pharmingen, San Diego, CA, USA). After
incubation for 40 min at 37 1C, the fluorescence was analyzed in a FACScalibur
Flow Cytometer (BD Biosciences), using CellQuest software (10. 000 events were
collected per sample). Alternations in the fluorescence intensity were determined
by comparing the levels of the treated cells to those of the controls.
Mitochondrial DW. Dc was determined in digitonin-permeabilized K562 cells
by changes in the fluorescence of rhodamine 123 at 37 1C in a Hitachi F-2500
fluorescence spectrophotometer (Tokyo, Japan) at 505/535 nm excitation/emission
wavelength pair with a slit width of 5/5 nm. Dc was also assessed by flow
cytometry using the lipophilic cationic dye JC-1 (5,5´,6,6´-tetrachloro-1,1´,3,
3´-tetraethylbenzimidazolcarbocyanine iodide; Molecular Probes, Eugene, OR,
USA). JC-1 is cationic dye that exhibits potential-dependent accumulation
in mitochondria by fluorescence emission shift from green (B520 nm) to red
(B590 nm). Consequently, mitochondrial depolarization is indicated by a
decrease in the red-green fluorescence intensity ratio. Cells were stimulated
(1 105 cells/ml) and after a 24-h incubation with the compound 7b, cells were
centrifuged and 1.0mg/ml JC-1 was added. To achieve total depolariztion, cells
were treated with 10mM carbonyl cyanide p-trifluoromethoxyphenylhydrazone.
After the incubation period the fluorescence was analyzed in a FACScalibur Flow
Cytometer (BD Biosciences), using CellQuest software (10 000 events were
collected per sample).
Cytochrome c release and nuclear alterations analyses. The
release of cytochrome c from mitochondria was estimated by using double-labeled
confocal cell imaging with MitoTracker Red CMXRos (Invitrogen, Carlsbad) and a
cytochrome c antibody. K562 cells (1 105/ml) were incubated for 12 h with
1.25 mM compound 7b in the absence and presence of pre-incubation with 1.0 mM
DTT. Then, cells were primarily labeled with 100 nM MitoTracker Red (Molecular
Probes) for 30 min at 37 1C. Then cells were washed with PBS and fixed with 2%
paraformaldehyde in PBS for 30 min. Fixed cells were permeabilized with 0.01%
saponin in PBS for 15 min and washed with PBS followed by a 2 h incubation at
room temperature with a monoclonal mouse antibody against human cytochrome
c 1 : 100 (0.5mg/ml, RD Systems, Minneapolis, MN, USA). After washing, cells
were incubated for 40 min with Alexa Fluor 488-conjugated goat anti-mouse
IgG (1 : 500; Molecular Probes) and 5.0mg/ml DAPI (Sigma-Aldrich, St. Louis,
MO, USA). Labeled cells were placed onto glass coverslips covered and mounted
in Fluoromount (Electron Microscopy Sciences, Hatfield, PA, USA). Micro-
scopy analyses were performed with a confocal laser scanning microscope
(Leica TCS-SP8 Microscope, Benshein, Germany) equipment with a  63 objective
(Plan-Neofluar, 1.4 numerical aperture) under oil immersion using LAS-AF software
(Leica). The pinhole device was adjusted to capture fluorescence of one airy unit in
one focal section. Alexa Fluor 488 was excited using an argon laser (lex¼ 488 nm)
and its emissions was detected from 500–550 nm. MitoTracker Red was excited
using HeNe laser (lex¼ 543 nm) and its emissions was detected from 560–610 nm.
Alexa Fluor 488 was excited using an argon laser (lex¼ 488 nm) and its emissions
was detected from 500–550 nm. DAPI was excited with a UV laser (lex¼ 353 nm)
and the emission was detected from 370–460 nm. In addition, DAPI staining was
used to observe the apoptotic nuclear morphology. The frequency of cells presenting
nuclear alterations was visually determined by observing and counting at least 100
cells per field of view in three different fields per sample. Each sample was done in
duplicate and the number of cells with nuclear alterations was expressed as a
percentage of the total number of cells.
Reduced protein thiol content and GSH levels. Protein SH groups
were quantified by using 5,50-dithiobis(2-nitrobenzoic) acid (DTNB, Ellman’s
reagent). After incubation time with compound 7b, cells were centrifuged during
10 min at 700 g. The pellet was treated with 0.2 ml of 6% trichloroacetic acid and
centrifuged at 6000 g during 15 min to precipitate the cellular proteins. The final
pellet was suspended with 1 ml of 0.5 M potassium phosphate buffer, pH 7.6. After
addition of 0.1 mM DTNB, absorbance was determined at 412 nm and the amount
of thiol groups was calculated from e¼ 13 600/M.34 GSH levels were determined
spectrofluorometrically using o-phthalaldehyde.35 The supernatant obtained after
acid precipitation (0.1 ml) was added to 1.9 ml of buffer, and after the addition of
0.05 mg/ml o-phthalaldehyde, the fluorescence was acquired at 350 and 420 nm,
excitation and emission wavelengths, respectively.
Scheme I Proposed mechanism for the compound 7b-induced apoptosis in
K562 leukemia cells. Compound 7b promotes the oxidation of the protein thiol
groups inside the cells. The oxidation of the protein thiol residues in the
mitochondrial membranes results in mitochondrial permeabilization associated to
the mitochondrial DC and cytochrome c release to the cytosol. In the presence of
dATP, cytochrome c induces the assembly of apoptosome and activation of pro-
caspase 9, which, in turn, activates the effector caspase 3. Thiol reducers (DTT,
NAC and GSH) inhibit the thiol oxidation and all downstream events that culminate
in apoptosis, showing the cell death is triggered by compound 7b-induced thiol
oxidation in K562 leukemia cells
Chart I Chemical structure of the cyclopalladated compound 7b [Pd2(R(þ ))C
2,
N-dmpa)2(m-dppe)Cl2]
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Statistical analyses. Values are the mean of at least three independent
experiments run in triplicate. Data for each assay are expressed as mean±
S.E.M. and were statistically analyzed by ANOVA. Multiple comparisons among
group mean differences were tested by using the Tukey post test. Differences
were considered significant when Po0.05. All graphical and statistical analyses
were performed with Origin Pro 8 software (Micronal Software, Inc., Northampton,
MA, USA).
Conflict of Interest
ACFC is the inventor on patents and patent applications related to use of
compound 7b. The other authors declare no conflict of interest.
Acknowledgements. This work was supported by grants from the Brazilian
agencies FAPESP (2012/12247-8) and CNPq (476824/2010-9). We thank
Prof. Rodrigo LOR Cunha for the drawing of the chemical structure.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Cancer statistics, 2009.
CA Cancer J Clin 2009; 59: 225–249.
2. Faderl S, Talpaz M, Estrov Z, O´Brien S, Kurzrock R, Kantarjian HM. The biology of chronic
myeloid leukemia. N Engl J Med 1999; 341: 164–172.
3. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
Nat Rev Cancer 2005; 5: 172–183.
4. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic
agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653.
5. Roychowdhury S, Talpaz M. Managing resistance in chronic myeloid leukemia. Blood Rev
2011; 25: 279–290.
6. Ramirez P, Dipersio JF. Therapy options in imatinib failures. Oncologist 2008; 13: 424–434.
7. Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A. Low BCR-ABL expression
levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia
under imatinib. Blood 2012; 119: 530–539.
8. Radich JP. Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
Cancer 2012; 118: 300–311.
9. Eiring AM, Khorashad JS, Morley K, Deininger MW. Advances in the treatment of chronic
myeloid leukemia. BMC Med 2011; 9: 1–6.
10. Seechurn CCCJ Kitching MO, Colacot TJ, Snieckus V. Palladium-catalysed cross-
coupling: a historical contextual perspective to the 2010 Nobel Prize. Angew Chem Int Ed
Engl 2012; 51: 5062–5085.
11. Gao E, Liu C, Zhu M, Lin H, Wu Q, Liu L. Current development of Pd(II) complexes as
potential antitumor agents. Anticancer Agents Med Chem 2009; 9: 356–368.
12. Caires AC. Recent advances involving palladium (II) complexes for the cancer therapy.
Anticancer Agents Med Chem 2007; 7: 484–491.
13. Rodrigues EG, Silva LS, Fausto DM, Hayashi MS, Dreher S, Santos EL et al.
Cyclopalladated compounds as chemotherapeutic agents: antitumor activity against a
murine melanoma cell line. Int J Cancer 2003; 107: 498–504.
14. Santana DP, Faria PA, Paredes-Gamero EJ, Caires ACF, Nantes IL, Rodrigues T.
Palladacycles catalyze the oxidation of critical thiols of the mitochondrial membrane
proteins and lead to mitochondrial permeabilization and cytochrome c release associated
with apoptosis. Biochem J 2009; 417: 247–256.
15. Barbosa CMV, Oliveira CR, Nascimento FD, Smith MCM, Fausto DM, Soufen MA et al.
Biphosphinic palladacycle complex mediates lysosomal-membrane permeabilization and
cell death in K562 leukaemia cells. Eur J Pharmacol 2006; 542: 37–47.
16. Oliveira CR, Barbosa CM, Nascimento FD, Lanetzki CS, Meneghin MB, Pereira FEG et al.
Pre-clinical antitumour evaluation of Biphosphinic Palladacycle Complex in human
leukaemia cells. Chem Biol Interact 2009; 177: 181–189.
17. Castilho RF, Kowaltowski AJ, Meinicke AR, Bechara EJH, Vercesi AE. Permeabilization of
the inner mitochondrial membrane by Ca2þ ions is stimulated by t-butyl hydroperoxide
and mediated by reactive oxygen species generated by mitochondria. Free Radic Biol Med
1995; 18: 479–486.
18. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and
beyond. Nat Rev Mol Cell Biol 2010; 11: 621–632.
19. Rasola A, Bernardi P. The mitochondrial permeability transition pore and its
involvement in cell death and in disease pathogenesis. Apoptosis 2007; 12:
815–833.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:
646–674.
21. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment.
Science 1993; 262: 1980–1981.
22. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat
Rev Cancer 2009; 9: 701–713.
23. Mello JV, Gordon DE, Cross NC, Goldman JM. The ABL-BCR fusion gene is expressed in
chronic myeloid leukemia. Blood 1993; 81: 158–165.
24. Rosenberg B, Van Camp L. The successful regression of large solid sarcoma 180 tumors
by platinum compounds. Cancer Res 1970; 30: 1799–1802.
25. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug
Discov 2005; 4: 307–320.
26. Matsuo AL, Silva LS, Torrecilhas AC, Pascoalino BS, Ramos TC, Rodrigues EG et al.
In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug
candidate for treatment of Chagas’ disease. Antimicrob Agents Chemother 2010; 54:
3318–3325.
27. Serrano FA, Matsuo AL, Monteforte PT, Bechara A, Smaili SS, Santana DP et al.
A cyclopalladated complex interacts with mitochondrial membrane thiol-groups and
induces the apoptotic intrinsic pathway in murine and cisplatin-resistant human tumor cells.
BMC Cancer 2011; 11: 296–312.
28. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug
Discov 2010; 9: 447–464.
29. Kowaltowski AJ, Castilho RF, Vercesi AE. Mitochondrial permeability transition and
oxidative stress. FEBS Lett 2001; 495: 12–15.
30. Zoratti M, Szabo` I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;
1241: 139–176.
31. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat
Rev Mol Cell Biol 2008; 9: 231–241.
32. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO-1/Fas) system in
drug-resistant cells. Leukemia 1997; 11: 1833–1841.
33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to
proliferation and cytotoxicity assay. J Immunol Methods 1983; 65: 55–63.
34. Jocelyn PC. Spectrophotometric assay of thiols. Methods Enzymol 1987; 143: 44–67.
35. Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced
glutathione in tissues. Anal Biochem 1976; 74: 214–226.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution-NonCommercial-
NoDerivs 3.0 Unported License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-nd/3.0/
Compound 7b-induced apoptosis in K562 leukemia cells
VWR Moraes et al
8
Cell Death and Disease
